A Multicenter, Prospective, Non-Interventional Real-World Study of Iparomlimab and Tuvonralimab Injection (QL1706) in the Treatment of Locally Advanced or Metastatic Solid Tumors

Inclusion Criteria: * 1\) Histologically or cytologically confirmed locally advanced or metastatic solid tumors with disease progression (radiographic or clinical) after ≥1 line of prior standard therapy, unsuitable for/intolerant to standard therapy. Includes but not limited to: Gastrointestinal tumors (colorectal cancer, hepatocellular carcinoma, esophageal cancer, biliary tract cancer, pancreatic cancer, gastric cancer), Breast cancer, Non-small cell lung cancer (NSCLC), Small cell lung cancer (SCLC), Soft tissue sarcoma; * 2\) ECOG performance status 0-2; * 3\) ≥1 measurable lesion per RECIST v1.1 ; * 4\) Adequate organ function meeting ALL criteria below: 1. Hematology (without transfusion/G-CSF support within 7 days): Absolute neutrophil count (ANC) ≥1.5×10⁹/L Platelets ≥100×10⁹/L Hemoglobin ≥90 g/L 2. Biochemistry : Total bilirubin (TBIL) ≤2×ULN ALT/AST ≤2.5×ULN (≤5×ULN if liver metastases present) Serum creatinine (Cr) ≤1.5×ULN Albumin ≥28 g/L 3. Urinalysis : Urine protein \<2+ (dipstick) If protein ≥2+, 24h urinary protein ≤1.0 g 4. Coagulation (without anticoagulants): PT/APTT/INR ≤1.5×ULN * 5\) Life expectancy ≥12 weeks; * 6\) Contraception : Females of childbearing potential or males with partners of childbearing potential must use effective contraception during treatment and for 6 months post-treatment; * 7\) Signed informed consent and protocol compliance. Exclusion Criteria: * 1\) Tumor-Related Conditions 1. Known CNS metastases (except those radiologically stable ≥4 weeks after radiotherapy); 2. Other malignancies within past 5 years, excluding: Cured basal/squamous cell skin cancer Localized low-risk prostate cancer Cervical/breast carcinoma in situ 3. Severe bone lesions from metastatic disease, including: Uncontrolled bone pain Pathologic fractures at critical sites (within 6 months) or impending spinal cord compression; 4. Uncontrolled effusions requiring recurrent drainage (pleural/pericardial/ascites), per investigator assessment. * 2\) Prior Anti-tumor Therapy 1. Prior systemic therapy with CTLA-4 inhibitors or other ICIs; 2. Any anti-tumor treatment within 4 weeks before first dose, including: Surgery/chemotherapy/palliative radiotherapy to non-target lesions/hormonal/targeted/biologic/immunotherapy; 3. Treatment-related toxicities not recovered to CTCAE grade ≤1 (exceptions: alopecia/platinum-induced neuropathy ≤ grade 2). * 3\) Comorbidities \& History 1. Arterial thromboembolism within 6 months (MI/unstable angina/stroke/TIA); 2. Symptomatic heart failure (NYHA class III-IV), unstable angina, or uncontrolled arrhythmia; 3. Severe pulmonary disease : ILD/COPD/symptomatic bronchospasm; 4. Active uncontrolled infection (≥CTCAE grade 2), including: HIV Active HBV (DNA ≥500 IU/mL) HCV (Ab+ with detectable RNA) HBV/HCV co-infection; 5. History of neurologic/psychiatric disorders; 6. Recent or current substance abuse; 7. Prior allogeneic organ/hematopoietic stem cell transplantation. * 4\) Hypersensitivity to study drug or its excipients. * 5\) Active autoimmune disease requiring treatment or history within 2 years. Exceptions: Vitiligo/alopecia/psoriasis not needing systemic therapy Hypothyroidism managed only with hormone replacement Type 1 diabetes controlled solely with insulin. * 6\) Pregnant/lactating women; * 7\) Any uncontrolled systemic disease increasing study risk (per investigator); * 8\) Other unsuitable conditions determined by investigator.